Developer docs
API playgroundTry for free, no card

Search company profiles

Namida Lab

Full company profile

uuid00039xc

Namestring
Namida Lab
Legal namestring
Namida Lab, Inc.
Websiteurl
namidalab.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Namida Lab, founded in 2019 and headquartered in Fayetteville, Arkansas, is a clinical-stage biotechnology company that has built a tear-based proteomic diagnostic platform for cancer screening. The core scientific thesis is that tears, unlike blood, lack large masking components such as albumin and hemoglobin, making small cancer-associated protein biomarkers easier to isolate and quantify. Namida operates a high-complexity CLIA-certified laboratory and has developed and validated an assay measuring two tear-based protein biomarkers associated with breast abnormalities, reporting 92% sensitivity and 58% specificity in work using 847 individually collected tear samples.

The company commercializes two product lines built on the same biomarker science: Auria, a direct-to-consumer at-home breast health assessment test sold through auria.care in the U.S. and Canada and eligible for FSA/HSA reimbursement, and Melody, a prescription-based clinical version targeted at healthcare providers. Auria+ is an add-on tier that bundles video consultations with Breast Health Educators. The diagnostic algorithm was developed using logistic regression on protein concentration data and was further refined through a partnership with Pattern Computer, whose Pattern Discovery Engine improved predictive accuracy and shortened development timelines. Namida also built a HIPAA-compliant iOS/Android consumer application with Helios Software to support clinical trial onboarding and consent.

Revenue mechanics combine one-time DTC kit sales, recurring CLIA-certified laboratory testing services, and (historically) transaction-fee COVID-19 antibody testing. The go-to-market is multi-channel: direct e-commerce to consumers, enterprise/B2B partnerships with breast centers and employers, event-driven clinical trial recruitment, and a series of research collaborations with high-profile clinical institutions including MD Anderson Cancer Center, UTMB, CARTI, Arkansas Urology, and Parkhill The Clinic for Women. Approximately $5.05M was raised in 2021; the team is roughly 10 people; Auria won the 2023 Edison Awards Top Intelligent Diagnostics Award. Active research now extends beyond breast cancer to ovarian, prostate, melanoma, pancreatic, and colon indications.

Short descriptiontext

Namida Lab is a Fayetteville, Arkansas-based biotechnology company developing tear-based proteomic diagnostic tests, serving individual consumers through its Auria at-home breast health assessment and clinicians through its Melody clinical screening product.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersFayetteville, United States
HQ citystring
Fayetteville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tear-based diagnostics, breast cancer screening, proteomic biomarkers, at-home diagnostic tests, biotech diagnostics
Industry2 codes
PRIMARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Cancer Diagnostics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1At-home test kit sales
TypeOne Time License
Description

Direct-to-consumer sales of Auria breast health assessment test kits through auria.care website. Currently not covered by insurance but accepted with FSA/HSA accounts.

auria.care
2Laboratory testing services
TypeSubscription Recurring
Description

CLIA-certified lab processing of tear samples with provider-certified results delivered to consumers.

auria.care
3COVID-19 antibody testing (historical)
TypeTransaction Fee
Description

Serological antibody testing services primarily for employers and healthcare workers during the pandemic.

namidalab.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details3 tiers
1Auria at-home breast health assessment test
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Price not publicly disclosed on website; available for purchase online. FSA/HSA eligible.

auria.care
2COVID-19 antibody test (general public)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$99 per test for general public

namidalab.com
3COVID-19 antibody test (healthcare workers, first responders, educators)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$69 per test (discounted pricing)

namidalab.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Auria
Description

At-home breast health assessment test powered by tears for early detection of breast cancer risk

auria.care
+1 more record
Core offering1 text field

Namida Lab develops tear-based proteomic diagnostic tests for cancer screening. Its flagship products include Auria, an at-home breast health assessment test sold direct-to-consumer, and Melody, a prescription-based tear-derived breast cancer screening test for clinical settings. Both products analyze protein biomarkers in tear fluid to detect breast abnormalities, processed through the company's CLIA-certified laboratory in Fayetteville, Arkansas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 92% sensitivity for breast cancer detection
+4 more records
Product overview1 text field

Namida Lab offers two related tear-based breast cancer screening products: Auria™ (direct-to-consumer) and Melody® (prescription/clinical). Auria™ is an at-home breast health assessment that women can purchase online, while Melody® is available through healthcare providers. Both products analyze protein biomarkers in tears to detect breast abnormalities. Auria+ adds consultation services with Breast Health Educators to the base Auria offering. The company operates a CLIA-certified laboratory to process tear samples and deliver results.

Product and service4 records
1Auria
CategoryAt-home diagnostic test
Description

An at-home breast health assessment test that uses protein biomarkers found in tears to detect potential breast abnormalities. The non-invasive test provides personalized results and recommendations for women ages 30 and over, designed to supplement routine mammogram screening. Available in the U.S. and Canada.

2Auria+
3Melody
CategoryClinical diagnostic test
Description

Prescription-based tear-derived breast cancer screening test designed for use in clinical settings. The lab-developed test analyzes protein biomarkers from tears to assess breast cancer risk and is intended to supplement routine screening mammography.

4COVID-19 Antibody Test
CategoryDiagnostic testing service
Description

Serological COVID-19 antibody testing services offered primarily to employers and healthcare workers during the pandemic. Priced at $99 for general public and $69 for healthcare workers, first responders, and educators.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership to expand early breast cancer detection through Auria at-home breast health assessment, empowering women and encouraging early detection.

2American Cancer Society National Breast Cancer Roundtable
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Namida joined ACS National Breast Cancer Roundtable to contribute to national breast cancer early detection initiatives.

namidalab.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Namida attended CGI Greenhouse 2023 meeting as part of commitment to global health initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

12-week clinical research study on Melody tear-based breast cancer screening test with recently diagnosed breast cancer patients not yet in treatment. Dr. Suzanne Klimberg serving as principal investigator.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Recruitment site for clinical trials around Melody for dense breast tissue application. Dr.s Robert Hix and Paige Partridge recruiting patients.

6Arkansas Urology
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for prostate cancer screening study collecting tear samples to identify proteins that could lead to early cancer detection test for prostate cancer.

namidalab.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

10-month study collecting tear samples from cancer patients diagnosed with breast, ovarian, prostate, melanoma, pancreatic, or colon cancer. CARTI has 18 treatment locations in 15 Arkansas communities.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Clinical study for women with dense breast tissue evaluating Melody tear-based screening as supplemental tool to mammography. 100 women enrolled over 6 months.

Strategic tierCoreTypeTechnology or Integration
Description

AI partnership applying Pattern Discovery Engine to Namida Lab data resulting in significant improvement to predictive accuracy for breast cancer screening and accelerated development timeline.

Strategic tierCoreTypeTechnology or Integration
Description

Boston-based health IT partnership to build HIPAA-compliant consumer app for clinical trial onboarding, consent, and health information collection available on iOS and Android.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for study of breast cancer screening test with community clinic in Arkansas.

12Heartland Pharmacy
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Pharmacy partnership for COVID-19 antibody testing collection at Fayetteville and Rogers locations, expanded to Central Arkansas and River Valley.

namidalab.com
13Heights Corner Market
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Little Rock retail location for COVID-19 antibody testing services, adjacent to Heights Corner Market on Kavanaugh Blvd.

namidalab.com
14Dickson Street Clinic
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Downtown Fayetteville family medicine clinic partnership for COVID-19 antibody testing collection services.

namidalab.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1GRAIL
TypeDirect peer
Description

Developer of Galleri, a multi-cancer early-detection blood test. GRAIL is the closest analog to Namida's cancer-screening thesis: a novel-sample (blood vs. tears), non-imaging, early-detection screening test positioned for asymptomatic adults, with an identical regulatory and adoption pathway.

TypeBroad incumbent
Description

Public diagnostics company behind Cologuard (CRC screening) and the Oncotype DX franchise. Comparable as a stool/blood-based cancer screening platform that built direct-to-consumer, employer, and provider channels — directly relevant to Namida's commercial playbook.

TypeEmerging player
Description

Molecular diagnostics company using novel assay approaches (e.g., UNITY fetal screen, Northstar liquid biopsy). Comparable as a small, science-driven specialty lab using novel sample/assay chemistry to enter mainstream screening.

TypeEmerging player
Description

Cell-free DNA-based oncology and reproductive health testing company. Comparable as a blood-based molecular diagnostics platform pursuing multi-cancer screening applications and similar specialty-lab business model.

TypeDirect peer
Description

At-home diagnostics company offering lab-based health and cancer screening kits via DTC e-commerce. Comparable sample collection, lab processing, and consumer health GTM.

TypeEmerging player
Description

Population-scale genetic testing and cancer screening company with employer and health system channels. Comparable as a specialty lab offering cancer-risk screening with similar B2B enterprise motion.

TypeEmerging player
Description

Breast density analytics and supplemental screening software for mammography. Highly comparable as a breast-screening adjunct focused on dense-breast tissue, the same unmet need Auria targets.

TypeBroad incumbent
Description

Dominant mammography and women's health diagnostics incumbent. Auria is explicitly positioned as a supplemental tool to mammography, making Hologic the primary incumbent whose installed base and clinical relationships Auria must coexist with in breast centers.

TypeBroad incumbent
Description

Established molecular diagnostics company with breast cancer risk tests (BRACAnalysis, RiskScore). Comparable as an incumbent genetic/molecular diagnostics franchise in breast cancer risk assessment that Auria could partner with or compete against on clinical-channel access.

TypeDirect peer
Description

Direct-to-consumer at-home diagnostics platform selling lab-based test kits online (FSA/HSA, no insurance). Most directly comparable to Auria's GTM motion, fulfillment model, and consumer-pay positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Namida Lab

Cancer Diagnosticsnamidalab.com

Namida Lab is a Fayetteville, Arkansas-based biotechnology company developing tear-based proteomic diagnostic tests, serving individual consumers through its Auria at-home breast health assessment and clinicians through its Melody clinical screening product.

What Namida Lab does

Namida Lab, founded in 2019 and headquartered in Fayetteville, Arkansas, is a clinical-stage biotechnology company that has built a tear-based proteomic diagnostic platform for cancer screening. The core scientific thesis is that tears, unlike blood, lack large masking components such as albumin and hemoglobin, making small cancer-associated protein biomarkers easier to isolate and quantify. Namida operates a high-complexity CLIA-certified laboratory and has developed and validated an assay measuring two tear-based protein biomarkers associated with breast abnormalities, reporting 92% sensitivity and 58% specificity in work using 847 individually collected tear samples.

The company commercializes two product lines built on the same biomarker science: Auria, a direct-to-consumer at-home breast health assessment test sold through auria.care in the U.S. and Canada and eligible for FSA/HSA reimbursement, and Melody, a prescription-based clinical version targeted at healthcare providers. Auria+ is an add-on tier that bundles video consultations with Breast Health Educators. The diagnostic algorithm was developed using logistic regression on protein concentration data and was further refined through a partnership with Pattern Computer, whose Pattern Discovery Engine improved predictive accuracy and shortened development timelines. Namida also built a HIPAA-compliant iOS/Android consumer application with Helios Software to support clinical trial onboarding and consent.

Revenue mechanics combine one-time DTC kit sales, recurring CLIA-certified laboratory testing services, and (historically) transaction-fee COVID-19 antibody testing. The go-to-market is multi-channel: direct e-commerce to consumers, enterprise/B2B partnerships with breast centers and employers, event-driven clinical trial recruitment, and a series of research collaborations with high-profile clinical institutions including MD Anderson Cancer Center, UTMB, CARTI, Arkansas Urology, and Parkhill The Clinic for Women. Approximately $5.05M was raised in 2021; the team is roughly 10 people; Auria won the 2023 Edison Awards Top Intelligent Diagnostics Award. Active research now extends beyond breast cancer to ovarian, prostate, melanoma, pancreatic, and colon indications.

Namida Lab firmographics

Firmographics
Name
Namida Lab
Legal name
Namida Lab, Inc.
Website
https://namidalab.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Namida Lab is a Fayetteville, Arkansas-based biotechnology company developing tear-based proteomic diagnostic tests, serving individual consumers through its Auria at-home breast health assessment and clinicians through its Melody clinical screening product.
Ownership category
akta.pro rank

Namida Lab industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Tear-based diagnostics
  • Breast cancer screening
  • Proteomic biomarkers
  • At-home diagnostic tests
  • Biotech diagnostics

Where Namida Lab is headquartered

Location

Headquarters

HQ city
Fayetteville
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Namida Lab business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. At-home test kit sales: Direct-to-consumer sales of Auria breast health assessment test kits through auria.care website. Currently not covered by insurance but accepted with FSA/HSA accounts.
  2. Laboratory testing services: CLIA-certified lab processing of tear samples with provider-certified results delivered to consumers.
  3. COVID-19 antibody testing (historical): Serological antibody testing services primarily for employers and healthcare workers during the pandemic.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAuria at-home breast health assessment test
Unit PricingPay-as-you-goCOVID-19 antibody test (general public)
Unit PricingPay-as-you-goCOVID-19 antibody test (healthcare workers, first responders, educators)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Namida Lab product offering

Product offering

Core offering

Namida Lab develops tear-based proteomic diagnostic tests for cancer screening. Its flagship products include Auria, an at-home breast health assessment test sold direct-to-consumer, and Melody, a prescription-based tear-derived breast cancer screening test for clinical settings. Both products analyze protein biomarkers in tear fluid to detect breast abnormalities, processed through the company's CLIA-certified laboratory in Fayetteville, Arkansas.

Product overview

Namida Lab offers two related tear-based breast cancer screening products: Auria™ (direct-to-consumer) and Melody® (prescription/clinical). Auria™ is an at-home breast health assessment that women can purchase online, while Melody® is available through healthcare providers. Both products analyze protein biomarkers in tears to detect breast abnormalities. Auria+ adds consultation services with Breast Health Educators to the base Auria offering. The company operates a CLIA-certified laboratory to process tear samples and deliver results.

Differentiator

Problem solved

Functional benefit

Brands

  • Auria: At-home breast health assessment test powered by tears for early detection of breast cancer risk
  • Melody

Products and services

  • Auria An at-home breast health assessment test that uses protein biomarkers found in tears to detect potential breast abnormalities. The non-invasive test provides personalized results and recommendations for women ages 30 and over, designed to supplement routine mammogram screening. Available in the U.S. and Canada.
  • Auria+
  • Melody Prescription-based tear-derived breast cancer screening test designed for use in clinical settings. The lab-developed test analyzes protein biomarkers from tears to assess breast cancer risk and is intended to supplement routine screening mammography.
  • COVID-19 Antibody Test Serological COVID-19 antibody testing services offered primarily to employers and healthcare workers during the pandemic. Priced at $99 for general public and $69 for healthcare workers, first responders, and educators.

Quantifiable outcome

  • 92% sensitivity for breast cancer detection
  • +4 more outcomes

Companies that use Namida Lab

Customer profile

Named customers7 records

Segments1 record

Ideal customer profiles3 records

Namida Lab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Namida Lab partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core, major and minor.

  • Healthyr PartnerscoreStrategic or Co-development PartnerStrategic partnership to expand early breast cancer detection through Auria at-home breast health assessment, empowering women and encouraging early detection.
  • American Cancer Society National Breast Cancer RoundtablemajorStrategic or Co-development PartnerNamida joined ACS National Breast Cancer Roundtable to contribute to national breast cancer early detection initiatives.
  • Clinton Global Initiative (CGI) GreenhousemajorStrategic or Co-development PartnerNamida attended CGI Greenhouse 2023 meeting as part of commitment to global health initiatives.
  • University of Texas Medical Branch (UTMB)coreStrategic or Co-development Partner12-week clinical research study on Melody tear-based breast cancer screening test with recently diagnosed breast cancer patients not yet in treatment. Dr. Suzanne Klimberg serving as principal investigator.
  • Parkhill The Clinic for WomencoreStrategic or Co-development PartnerRecruitment site for clinical trials around Melody for dense breast tissue application. Dr.s Robert Hix and Paige Partridge recruiting patients.
  • Arkansas UrologycoreStrategic or Co-development PartnerPartnership for prostate cancer screening study collecting tear samples to identify proteins that could lead to early cancer detection test for prostate cancer.
  • CARTIcoreStrategic or Co-development Partner10-month study collecting tear samples from cancer patients diagnosed with breast, ovarian, prostate, melanoma, pancreatic, or colon cancer. CARTI has 18 treatment locations in 15 Arkansas communities.
  • MD Anderson Cancer CentermajorStrategic or Co-development PartnerClinical study for women with dense breast tissue evaluating Melody tear-based screening as supplemental tool to mammography. 100 women enrolled over 6 months.
  • Pattern ComputercoreTechnology or IntegrationAI partnership applying Pattern Discovery Engine to Namida Lab data resulting in significant improvement to predictive accuracy for breast cancer screening and accelerated development timeline.
  • Helios SoftwarecoreTechnology or IntegrationBoston-based health IT partnership to build HIPAA-compliant consumer app for clinical trial onboarding, consent, and health information collection available on iOS and Android.
  • Community ClinicminorStrategic or Co-development PartnerPartnership for study of breast cancer screening test with community clinic in Arkansas.
  • Heartland PharmacyminorChannel Partner/ Reseller/ DistributorPharmacy partnership for COVID-19 antibody testing collection at Fayetteville and Rogers locations, expanded to Central Arkansas and River Valley.
  • Heights Corner MarketminorChannel Partner/ Reseller/ DistributorLittle Rock retail location for COVID-19 antibody testing services, adjacent to Heights Corner Market on Kavanaugh Blvd.
  • Dickson Street ClinicminorChannel Partner/ Reseller/ DistributorDowntown Fayetteville family medicine clinic partnership for COVID-19 antibody testing collection services.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Namida Lab competitors and assessment

Company assessment

Direct peers

  • GRAIL: Developer of Galleri, a multi-cancer early-detection blood test. GRAIL is the closest analog to Namida's cancer-screening thesis: a novel-sample (blood vs. tears), non-imaging, early-detection screening test positioned for asymptomatic adults, with an identical regulatory and adoption pathway.
  • LetsGetChecked: At-home diagnostics company offering lab-based health and cancer screening kits via DTC e-commerce. Comparable sample collection, lab processing, and consumer health GTM.
  • Everlywell: Direct-to-consumer at-home diagnostics platform selling lab-based test kits online (FSA/HSA, no insurance). Most directly comparable to Auria's GTM motion, fulfillment model, and consumer-pay positioning.

Broad incumbents

  • Exact Sciences: Public diagnostics company behind Cologuard (CRC screening) and the Oncotype DX franchise. Comparable as a stool/blood-based cancer screening platform that built direct-to-consumer, employer, and provider channels — directly relevant to Namida's commercial playbook.
  • Hologic: Dominant mammography and women's health diagnostics incumbent. Auria is explicitly positioned as a supplemental tool to mammography, making Hologic the primary incumbent whose installed base and clinical relationships Auria must coexist with in breast centers.
  • Myriad Genetics: Established molecular diagnostics company with breast cancer risk tests (BRACAnalysis, RiskScore). Comparable as an incumbent genetic/molecular diagnostics franchise in breast cancer risk assessment that Auria could partner with or compete against on clinical-channel access.

Emerging players

  • BillionToOne: Molecular diagnostics company using novel assay approaches (e.g., UNITY fetal screen, Northstar liquid biopsy). Comparable as a small, science-driven specialty lab using novel sample/assay chemistry to enter mainstream screening.
  • Natera: Cell-free DNA-based oncology and reproductive health testing company. Comparable as a blood-based molecular diagnostics platform pursuing multi-cancer screening applications and similar specialty-lab business model.
  • Color Health: Population-scale genetic testing and cancer screening company with employer and health system channels. Comparable as a specialty lab offering cancer-risk screening with similar B2B enterprise motion.
  • Volpara Health: Breast density analytics and supplemental screening software for mammography. Highly comparable as a breast-screening adjunct focused on dense-breast tissue, the same unmet need Auria targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Namida Lab social profiles

Digital presence

Namida Lab compliance and trust

Trust signal

Compliance1 record

Namida Lab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Namida Lab leadership team

Management profile

Number of profiles

Profiles5 records

Namida Lab funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Namida Lab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Namida Lab

What does Namida Lab do?

Namida Lab develops tear-based proteomic diagnostic tests for cancer screening. Its flagship products include Auria, an at-home breast health assessment test sold direct-to-consumer, and Melody, a prescription-based tear-derived breast cancer screening test for clinical settings. Both products analyze protein biomarkers in tear fluid to detect breast abnormalities, processed through the company's CLIA-certified laboratory in Fayetteville, Arkansas.

Is Namida Lab a public or private company?

Namida Lab is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Namida Lab founded?

Namida Lab was founded in 2019. It employs 1 to 10 people.

Where is Namida Lab based?

Namida Lab is headquartered in Fayetteville, United States, in the North America region.

How does Namida Lab make money?

Three revenue lines are on record. At-home test kit sales are the primary driver. The others are laboratory testing services and COVID-19 antibody testing (historical).

Who are Namida Lab's main competitors?

Direct peers on record are GRAIL, LetsGetChecked and Everlywell. Broad incumbents are Exact Sciences, Hologic and Myriad Genetics. Emerging players are BillionToOne, Natera, Color Health and Volpara Health.

Does Namida Lab have an API?

No public API is recorded for Namida Lab.

What industry is Namida Lab in?

Namida Lab's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAGANAB, Proteomics & Mass Spectrometry Services. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAuria is Empowering Women and Saving Lives through Early Breast Cancer DetectionNamida Lab is promoting its Auria test, the first at-home biological breast cancer screening tool, during Breast Cancer Awareness Month to encourage early detection. The product utilizes tear biomarkers to assess risk and complements traditional mammography by providing patients with a clinical consultation to guide further medical action.PR NewswireNamida Joins The American Cancer Society National Breast Cancer RoundtableNamida Lab, Inc., an Arkansas-based tear-based biotech company, has been accepted as a member of the American Cancer Society National Breast Cancer Roundtable (ACS NBCRT), a national coalition dedicated to accelerating progress across the breast cancer spectrum through strategic partnerships. Dr. Anna Daily, Namida's Chief Scientific Officer and inventor of Auria, the first at-home biological breast cancer screening test powered by tears, will attend the inaugural ACS NBCRT Strategic Planning Meeting in Houston, Texas this September. The membership aligns Namida's mission to improve access to breast cancer screening, particularly for rural women and historically excluded communities, with ACS NBCRT's goal of eliminating disparities and reducing mortality.Talk Business & PoliticsNamida Lab wins gold at 2023 Edison Awards - Talk Business & PoliticsNamida Lab won gold at the 2023 Edison Awards for its at-home breast health test Auria, which uses teardrops to identify protein biomarkers. The $159 test is available online and at Amazon and Walmart, and the company plans to develop affordable cancer screening tools.SecSEC FORM DNamida Lab, Inc. filed a Form D with the SEC to announce an exempt securities offering under Rule 506(b) with a total offering amount of $5,050,000. The company, incorporated in Delaware and based in Arkansas, has sold its equity securities to four investors since the first sale on August 5, 2019. Proceeds from the offering are intended for general working capital purposes.Talk Business & PoliticsKeep your appointment - Talk Business & PoliticsA Wall Street Journal article warned that deferred cancer screenings during COVID-19 could cause 10,000 additional deaths from colon and breast cancer. Namida Lab's CEO Omid Moghadam introduced the Melody tear test, a noninvasive prescreening tool for dense-breasted women, with market launch expected in 2021.